Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 116
- Registration Number
- NCT02038946
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
🇬🇧Local Institution, Sutton, Surrey, United Kingdom
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT02011945
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦QEII Health Sciences Centre-VG Site, Halifax, Nova Scotia, Canada
🇩🇪Campus Virchow Klinikum Der Charite, Berlin, Germany
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 353
- Registration Number
- NCT02009449
- Locations
- 🇺🇸
UCLA Medical Hematology & Oncology, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 14
- Registration Number
- NCT01998126
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
- Conditions
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 143
- Registration Number
- NCT01928576
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸UPMC Cancer Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 142
- Registration Number
- NCT01927419
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 146
- Registration Number
- NCT01896999
- Locations
- 🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 117
- Registration Number
- NCT01721759
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Winship Cancer Institute., Atlanta, Georgia, United States
🇺🇸Providence Cancer Institute, Southfield, Michigan, United States
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 337
- Registration Number
- NCT01714739
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.